Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 8, 2008, Pages 2745-2750

  Randolph, John T ^a   Zhang, Xiaolin ^a   Huang, Peggy P ^a   Klein, Larry L ^a   Kurtz, Kevin A ^a   Konstantinidis, Alex K ^a   He, Wenping ^a   Kati, Warren M ^a   Kempf, Dale J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Azapeptide; HCV protease inhibitor; Macrocycle

Indexed keywords

CILUPREVIR; HETEROCYCLIC COMPOUND; MACROCYCLIC COMPOUND; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE INHIBITOR; TRIPEPTIDE DERIVATIVE; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ISOLATION; HEPATITIS C VIRUS; HYDROGEN BOND; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; PROTEIN CONFORMATION; PROTEIN STRUCTURE; REPLICON; VIRUS GENOME;

ANTIVIRAL AGENTS; AZA COMPOUNDS; CARRIER PROTEINS; CATALYSIS; MACROCYCLIC COMPOUNDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PEPTIDES; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 41849136891     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.02.053     Document Type: Article

References (23)

1. Kim W.R. Hepatology 36 (2002) s30
2. Cornberg M., Wedemeyer H., and Manns M.P. Curr. Gastroenterol. Rep. 4 (2002) 23
3. For a recent review on HCV antivirals, see:. Ni Z.-J., and Wagman S. Curr. Opin. Drug Disc. Dev. 7 (2004) 446
4. Also, see:. Bhopale G.M., and Nanda R.K. Hepatol. Res. 32 (2005) 146
5. For a recent review of NS3-4A protease inhibitors, see:. Thomson J.A., and Perni R.B. Curr. Opin. Drug Disc. Dev. 9 (2006) 1367
6. Also, see:. Sheldon J., Barreiro P., and Vincent V. Expert Opin. Invest. Drugs 16 (2007) 1171
7. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Boes M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.-M., Goudreau N., Kawal S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M.-A., Rancourt J., Sentjens R.E., St. George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Welden S.M., Yong C.-L., and Llinas-Brunet M. Nature 426 (2003) 186
8. Llinas-Brunet M., Bailey M.D., Bolger G., Brochu C., Faucher A.-M., Ferland J.M., Garneau M., Ghiro E., Gorys V., Grand-Maitre C., Halmos T., Lapeyre-Paquette N., Liard F., Poirer M., Rheaume M., Tsantrizos Y., and Lamarre D. J. Med. Chem. 47 (2004) 1605
9. Atazanavir is an aza-peptide HIV PI. For a recent review, see:. Perez-Elias M.J. Expert Opin. Pharmacother. 8 (2007) 689
10. Faucher A.-M., Bailey M.D., Beaulieu P.L., Brochu C., Duceppe J.-S., Ferland J.-M., Ghiro E., Gorys V., Halmos T., Kawai S.H., Poirer M., Simoneau B., Tantrizos Y.S., and Llinas-Brunet M. Org. Lett. 6 (2004) 2901
11. Tsantrizos Y.S., Ferland J.-M., McClory A., Poirier M., Farina V., Yee N.K., Wang X.J., Haddad N., Wei X., Xu J., and Zhang L. J. Organometal. Chem. 691 (2006) 5163
12. For a recent review on olefin metathesis, see:. Schrock R.R., and Hoveyda A.H. Angew. Chem. Int. Ed. Engl. 42 (2003) 4592
13. Tsantrizos, Y. S.; Cameron, D.; Faucher, A. -M.; Ghiro, E.; Goudreau, N.; Halmos, T.; Llinas-Brunet, M. U.S. Patent 6,608,027 B1, 2003.
14. Andre F., Vicherat A., Boussard G., Aubrey A., and Marraud M. J. Peptide Res. 50 (1997) 372
15. Andre F., Marraud M., and Boussard G. Tetr. Lett. 37 (1996) 183
16. We have observed a strong NOE between the P1 NH and P2 Hα in NMR spectra of non-aza tripeptide HCV PIs, including 1 and 2. This NOE is consistent with an extended conformation for the peptide portion of these compounds.
17. 13
18. For assay procedures, see:. Lu L., Pilot-Matias T.J., Stewart K.D., Randolph J.T., Pithawalla R., He W., Huang P.P., Klein L.L., Mo H., and Molla A. Antimicrob. Agents Chemother. 48 (2004) 2260
19. 6 sample to 60 °C to obtain useful NMR data for analysis.
20. Huang, P. P.; Randolph, J. T.; Flentge, C.; Klein, L. L.; Kurtz, K.; Konstantinidis, A.; Kati, W.; Zhang, X.; Stoll, V. S.; Kempf, D. J. 232nd ACS National Meeting, San Francisco, CA, Sept, 2006; MEDI-176.
21. 3.
22. 3 was not obtained.
23. The structures corresponding to compounds 9 (Fig. 3) and 10 (Fig. 5) were energy minimized using the CFF force field within Insight software (Accelrys, San Diego).